Anti-Surfactant Protein B (Mature) antibody [SPB02 (same as 1B9)] (ab3282)

Overview

• Product nameAnti-Surfactant Protein B (Mature) antibody [SPB02 (same as 1B9)]See all Surfactant Protein B (Mature) primary antibodies ...
• Description
  Mouse monoclonal [SPB02 (same as 1B9)] to Surfactant Protein B (Mature)
• Tested applicationsIHC-Fr, ICC/IF, IHC-P, WB more details
• Species reactivity
  Reacts with: Mouse, Human
  
• Immunogen

  Recombinant full length protein.

• Positive controlLung adenocarcinomas.
• General notes

  
  

  ProSPB is glycosylated in the Golgi apparatus and undergoes carboxy and amino terminal proteolysis by a cathepsin D like protease. Pulmonary surfactant is a complex mixture of phospholipids and proteins that is secreted from type II cells in alveoli and reduces the surface tension atthe alveolar air liquid interface, providing alveolar stability necessary for normal ventillation. Four distinct proteins isolated from pulmonary surfactant are termed surfactant proteins A, B, C and D. SP A (28 - 36 kDa) and SP D (43 kDa) are collagenous carbohydrate binding proteins, whereas SP B (8 - 9 kDa) and SP C (4 kDa) are non collagenous hydrophobic proteins. SP B is expressed in pulmonary adenocarcinomas with acinar, papillary, bronchioloalveolar, and solid growth patterns. Squamous cell and large cell carcinomas of the lung and nonpulmonary adenocarcinomas do not express SP B.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage buffer10mM PBS, pH7.4, 0.2%BSA, 0.09% sodium azide
• Concentration information loading...
• PurityProtein A purified
• Primary antibody notes ProSPB is glycosylated in the Golgi apparatus and undergoes carboxy and amino terminal proteolysis by a cathepsin D like protease. Pulmonary surfactant is a complex mixture of phospholipids and proteins that is secreted from type II cells in alveoli and reduces the surface tension atthe alveolar air liquid interface, providing alveolar stability necessary for normal ventillation. Four distinct proteins isolated from pulmonary surfactant are termed surfactant proteins A, B, C and D. SP A (28 - 36 kDa) and SP D (43 kDa) are collagenous carbohydrate binding proteins, whereas SP B (8 - 9 kDa) and SP C (4 kDa) are non collagenous hydrophobic proteins. SP B is expressed in pulmonary adenocarcinomas with acinar, papillary, bronchioloalveolar, and solid growth patterns. Squamous cell and large cell carcinomas of the lung and nonpulmonary adenocarcinomas do not express SP B.
• Clonality Monoclonal
• Clone numberSPB02 (same as 1B9)
• IsotypeIgG2a
• Light chain typekappa
• Research Areas
  • Metabolism
  • Types of disease
  • Cancer

  • Metabolism
  • Pathways and Processes
  • Metabolic signaling pathways
  • Lipid and lipoprotein metabolism
  • Lipases

  • Signal Transduction
  • Metabolism
  • Lipid metabolism

  • Cardiovascular
  • Lipids / Lipoproteins
  • Lipid Metabolism
  • Lipases

  • Cardiovascular
  • Blood
  • Other

Applications

Target

• FunctionPulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter.
• Involvement in diseaseDefects in SFTPB are the cause of pulmonary surfactant metabolism dysfunction type 1 (SMDP1) [MIM:265120]; also called pulmonary alveolar proteinosis due to surfactant protein B deficiency. A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.
  Genetic variations in SFTPB are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS) [MIM:267450]. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'. Note=A variation Ile to Thr at position 131 influences the association between specific alleles of SFTPA1 and respiratory distress syndrome in premature infants.
• Sequence similaritiesContains 1 saposin A-type domain.
  Contains 3 saposin B-type domains.
• Cellular localizationSecreted > extracellular space > surface film.

Target information above from: UniProt accession P07988 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 6439 Human
  • Entrez Gene: 20388 Mouse
  • Omim: 178640 Human
  • SwissProt: P07988 Human
  • SwissProt: P50405 Mouse
  • Unigene: 512690 Human
  • Unigene: 46033 Mouse

• Alternative names
  18 kDa pulmonary surfactant protein antibody18 kDa pulmonary-surfactant protein antibody6 kDa protein antibody

  PSPB antibodyPSPB_HUMAN antibodyPulmonary surfactant apoprotein PSP B antibodyPulmonary surfactant associated protein B 18kD antibodyPulmonary surfactant associated protein B antibodyPulmonary surfactant associated proteolipid SPL Phe antibodyPulmonary surfactant-associated protein B antibodyPulmonary surfactant-associated proteolipid SPL(Phe) antibodySFTB3 antibodySFTP3 antibodySFTPB antibodySFTPB surfactant antibodySP B antibodySP-B antibodySPB antibodySurfactant pulmonary associated protein B antibody

  see all

Anti-Surfactant Protein B (Mature) antibody [SPB02 (same as 1B9)] images

• 

  Immunohistochemistry (Frozen sections) - Surfactant Protein B (Mature) antibody [SPB02 (same as 1B9)] (ab3282)

  ab3282 at a 1/100 dilution staining Surfactant Protein B (Mature) from Mouse Tissue sections (Lung) by Immunohistochemistry (Frozen sections). The antibody was incubated with the tissue for 24 hours and then detected using an Alexa Fluor® 488 Goat anti-mouse IgG antibody.

  This image is courtesy of an Abreview submitted by an ananymous researcher on 5 January 2006.

  See Abreview